Scholars Central

Conference abstractPublished 26 Oct 2016

Inside track to an orphan designation

Authors: Timothy R Cote

Cote Orphan LLC, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

All too often, creators of new therapies for people with rare diseases will expend vast resources on drug discovery, manufacturing, clinical key opinion leaders and of course raising money but ignore regulatory affairs, assuming that will just itself somehow work out. In this presentation, Dr. Cote, previous Director of the FDA orphan drug office, will discuss the intricacies of the orphan drug designation in the US and in Europe, preparing for a winning pre-IND meeting, crafting clinical trials that make sense to regulators, special incentives like breakthrough therapy designation, the pediatric rare disease designation and the PRIME program will also be demystified.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Timothy R Cote”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels